EligibleTrials

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Recruiting · NCT07474792 · Interventional (participants receive a specific treatment) · Lead sponsor: Oruka Therapeutics, Inc.

View the official record on ClinicalTrials.gov →
Psoriasis

Interventions studied

ORKA-002Placebo

What this trial is about

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.

Who can take part

Age range
18 Years to 79 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

39 locations listed across 17 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.